CLEANSPARK, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CLEANSPARK, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $766.31M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $378.97M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $168.41M | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | $131.53M | Dec 3, 2024 |
| FY2022 | Sep 30, 2021 | $39.29M | Dec 15, 2022 |
| FY2021 | Sep 30, 2020 | $10.03M | Dec 14, 2021 |
| FY2021 | Sep 30, 2019 | $4.53M | Dec 17, 2020 |
| FY2019 | Sep 30, 2018 | $578.6K | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $448.0K | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | $82.0K | Jan 16, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2020 | $2.12M | Dec 17, 2020 |
| FY2021 | Sep 30, 2019 | $671.7K | Dec 17, 2020 |
| FY2019 | Sep 30, 2018 | $187.9K | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $151.7K | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | $50.8K | Jan 16, 2018 |
| FY2015 | Sep 30, 2014 | $1.9K | Dec 29, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $364.46M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($145.78M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | ($138.15M) | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | ($57.33M) | Dec 3, 2024 |
| FY2022 | Sep 30, 2021 | ($21.81M) | Dec 15, 2022 |
| FY2021 | Jun 30, 2021 | ($16.68M) | Dec 14, 2021 |
| FY2021 | Mar 31, 2021 | $7.40M | Dec 14, 2021 |
| FY2021 | Sep 30, 2020 | ($23.35M) | Dec 14, 2021 |
| FY2021 | Sep 30, 2019 | ($26.12M) | Dec 17, 2020 |
| FY2019 | Sep 23, 2019 | ($26.12M) | Dec 16, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $318.95M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($149.04M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | ($131.04M) | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | ($37.86M) | Dec 3, 2024 |
| FY2022 | Sep 30, 2021 | ($11.90M) | Dec 15, 2022 |
| FY2021 | Sep 30, 2020 | ($15.14M) | Dec 14, 2021 |
| FY2019 | Sep 30, 2019 | ($16.61M) | Dec 16, 2019 |
| FY2019 | Sep 30, 2018 | ($7.08M) | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | ($13.38M) | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | ($2.54M) | Jan 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Sep 30, 2018 | $7.2K | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $591 | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | $1.8K | Jan 16, 2018 |
| FY2016 | Sep 30, 2015 | $52.3K | Dec 30, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($461.03M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($233.66M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | ($17.25M) | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | $73.46M | Dec 3, 2024 |
| FY2022 | Sep 30, 2021 | ($23.99M) | Dec 15, 2022 |
| FY2021 | Sep 30, 2020 | ($6.64M) | Dec 14, 2021 |
| FY2021 | Sep 30, 2019 | ($5.70M) | Dec 17, 2020 |
| FY2019 | Sep 23, 2019 | ($5.70M) | Dec 16, 2019 |
| FY2018 | Sep 30, 2018 | ($1.26M) | Jan 15, 2019 |
| FY2019 | Sep 23, 2018 | ($1.26M) | Dec 16, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $19.29M | Dec 15, 2022 |
| FY2022 | Sep 30, 2021 | $139.23M | Dec 15, 2022 |
| FY2021 | Sep 30, 2020 | $34.9K | Dec 14, 2021 |
| FY2019 | Sep 23, 2019 | $102.8K | Dec 16, 2019 |
| FY2018 | Sep 30, 2018 | $15.2K | Jan 15, 2019 |
| FY2019 | Sep 23, 2018 | $15.2K | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $5.1K | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | $9.7K | Jan 16, 2018 |
| FY2016 | Sep 30, 2015 | $77.0K | Dec 30, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.18B | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $1.96B | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $761.58M | Dec 3, 2024 |
| FY2023 | Sep 30, 2022 | $452.63M | Dec 1, 2023 |
| FY2022 | Sep 30, 2021 | $317.47M | Dec 15, 2022 |
| FY2021 | Jun 30, 2021 | $297.49M | Dec 14, 2021 |
| FY2021 | Mar 31, 2021 | $292.61M | Dec 14, 2021 |
| FY2021 | Sep 30, 2020 | $22.34M | Dec 14, 2021 |
| FY2021 | Sep 30, 2019 | $23.43M | Dec 17, 2020 |
| FY2019 | Sep 30, 2018 | $17.56M | Dec 16, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.01B | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $201.82M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $85.91M | Dec 3, 2024 |
| FY2023 | Sep 30, 2022 | $48.61M | Dec 1, 2023 |
| FY2022 | Sep 30, 2021 | $11.76M | Dec 15, 2022 |
| FY2021 | Jun 30, 2021 | $15.69M | Dec 14, 2021 |
| FY2021 | Mar 31, 2021 | $8.89M | Dec 14, 2021 |
| FY2021 | Sep 30, 2020 | $5.91M | Dec 14, 2021 |
| FY2021 | Sep 30, 2019 | $4.55M | Dec 17, 2020 |
| FY2019 | Sep 30, 2018 | $1.50M | Dec 16, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.18B | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $1.76B | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $675.67M | Nov 25, 2025 |
| FY2025 | Sep 30, 2022 | $404.01M | Nov 25, 2025 |
| FY2024 | Sep 30, 2021 | $305.72M | Dec 3, 2024 |
| FY2021 | Jun 30, 2021 | $281.80M | Dec 14, 2021 |
| FY2021 | Mar 31, 2021 | $283.72M | Dec 14, 2021 |
| FY2022 | Sep 30, 2020 | $16.43M | Dec 15, 2022 |
| FY2021 | Sep 30, 2019 | $18.89M | Dec 14, 2021 |
| FY2021 | Sep 30, 2018 | $16.06M | Dec 17, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $131.66M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $8.04M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $8.04M | Nov 25, 2025 |
| FY2025 | Sep 30, 2022 | $0 | Nov 25, 2025 |
| FY2024 | Sep 30, 2021 | $12.05M | Dec 3, 2024 |
| FY2021 | Jun 30, 2021 | $31.80M | Dec 14, 2021 |
| FY2021 | Mar 31, 2021 | $32.03M | Dec 14, 2021 |
| FY2021 | Sep 30, 2020 | $5.90M | Dec 14, 2021 |
| FY2021 | Sep 30, 2019 | $4.92M | Dec 17, 2020 |
| FY2019 | Sep 30, 2018 | $4.92M | Dec 16, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($125.89M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($479.22M) | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | ($334.20M) | Dec 3, 2024 |
| FY2023 | Sep 30, 2022 | ($196.05M) | Dec 1, 2023 |
| FY2022 | Sep 30, 2021 | ($138.39M) | Dec 15, 2022 |
| FY2021 | Sep 30, 2020 | ($116.40M) | Dec 14, 2021 |
| FY2021 | Sep 30, 2019 | ($93.06M) | Dec 17, 2020 |
| FY2019 | Sep 30, 2018 | ($66.94M) | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | ($19.93M) | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | ($6.43M) | Jan 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $42.97M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $121.22M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $29.22M | Dec 3, 2024 |
| FY2023 | Sep 30, 2022 | $20.46M | Dec 1, 2023 |
| FY2022 | Sep 30, 2021 | $18.04M | Dec 15, 2022 |
| FY2021 | Sep 30, 2020 | $3.13M | Dec 14, 2021 |
| FY2021 | Sep 30, 2019 | $7.84M | Dec 14, 2021 |
| FY2019 | Sep 23, 2019 | $7.84M | Dec 16, 2019 |
| FY2021 | Sep 30, 2018 | $412.8K | Dec 17, 2020 |
| FY2019 | Sep 23, 2018 | $412.8K | Dec 16, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $644.59M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $7.18M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $8.91M | Dec 3, 2024 |
| FY2023 | Sep 30, 2022 | $13.43M | Dec 1, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2023 | (1) | Nov 25, 2025 |
| FY2019 | Sep 30, 2019 | (6) | Dec 16, 2019 |
| FY2019 | Sep 30, 2018 | (13) | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | 0 | Jan 16, 2018 |
| FY2016 | Sep 30, 2015 | 0 | Dec 30, 2016 |
| FY2015 | Sep 30, 2014 | 0 | Dec 29, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2023 | (1) | Nov 25, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 284.33M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | 270.90M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | 160.18M | Dec 3, 2024 |
| FY2023 | Mar 31, 2023 | 96.95M | Dec 1, 2023 |
| FY2023 | Sep 30, 2022 | 55.66M | Dec 1, 2023 |
| FY2022 | Sep 30, 2021 | 37.40M | Dec 15, 2022 |
| FY2021 | Sep 30, 2020 | 17.39M | Dec 14, 2021 |
| FY2021 | Sep 30, 2019 | 4.68M | Dec 17, 2020 |
| FY2013 | Sep 30, 2013 | 950,687 | Dec 30, 2013 |
| FY2013 | Sep 30, 2012 | 950,687 | Dec 30, 2013 |